An anthracycline antibiotic that has formula C27H29NO11.
Chemical ID:
MESH:D004317
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Doxorubicin results in increased expression of TP53 mRNA; Doxorubicin results in increased expression of TP53 protein; Doxorubicin results in increased expression of TP53 protein modified form
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Doxorubicin results in increased phosphorylation of TP53 protein]; 4-(((4-carboxybutyl) (2- (5-fluoro-2-((4'-(trifluoromethyl) biphenyl-4-yl)methoxy)phenyl)ethyl) amino)methyl)benzoic acid inhibits the reaction [Doxorubicin results in increased phosphorylation of TP53 protein]; 7-monohydroxyethylrutoside inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; [Doxorubicin affects the reaction [TP53 protein binds to HSPB1 protein]] which results in increased expression of CDKN1A protein; [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; caryophyllene inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Curcumin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Doxorubicin affects the reaction [TP53 protein binds to HSPB1 protein]; Doxorubicin promotes the reaction [SIRT6 protein binds to TP53 protein]; Doxorubicin promotes the reaction [TP53 protein binds to BAX promoter]; Doxorubicin promotes the reaction [TP53 protein binds to BCL2 promoter]; Doxorubicin promotes the reaction [TP53 protein binds to FAS promoter]; Doxorubicin promotes the reaction [TP53 protein binds to FASLG promoter]; Doxorubicin results in increased expression of and results in increased localization of TP53 protein modified form; Doxorubicin results in increased expression of and results in increased phosphorylation of and results in increased stability of and results in increased activity of TP53 protein; Doxorubicin results in increased phosphorylation of and results in increased localization of TP53 protein; Exenatide inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Ginkgo biloba extract inhibits the reaction [Doxorubicin results in increased expression of TP53 mRNA]; iodopravadoline inhibits the reaction [caryophyllene inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]]; kaempferol inhibits the reaction [Doxorubicin promotes the reaction [TP53 protein binds to BAX promoter]]; kaempferol inhibits the reaction [Doxorubicin results in increased expression of TP53 mRNA]; pifithrin inhibits the reaction [Doxorubicin results in increased expression of and results in increased localization of TP53 protein modified form]; pifithrin inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein]; pifithrin inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased localization of TP53 protein]; Propofol inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Quercetin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; SHC1 protein promotes the reaction [Doxorubicin results in increased expression of TP53 protein]; SIRT6 protein inhibits the reaction [Doxorubicin promotes the reaction [TP53 protein binds to FAS promoter]]; SIRT6 protein inhibits the reaction [Doxorubicin promotes the reaction [TP53 protein binds to FASLG promoter]]; SIRT6 protein inhibits the reaction [Doxorubicin results in increased acetylation of TP53 protein]; U 0126 inhibits the reaction [Doxorubicin results in increased expression of and results in increased localization of TP53 protein modified form]; U 0126 inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased localization of TP53 protein]; Valsartan inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]
TRP53 gene mutant form results in decreased susceptibility to Doxorubicin; TRP53 gene polymorphism results in decreased susceptibility to Doxorubicin; TRP53 protein mutant form results in decreased susceptibility to Doxorubicin
Doxorubicin results in increased expression of TP53 protein; Doxorubicin results in increased expression of TRP53 mRNA; Doxorubicin results in increased expression of TRP53 protein; Doxorubicin results in increased expression of TRP53 protein modified form
Doxorubicin results in increased expression of TP53; Doxorubicin results in increased expression of TP53 mRNA; Doxorubicin results in increased expression of TP53 protein; Doxorubicin results in increased expression of TP53 protein modified form
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]]; [Doxorubicin affects the reaction [TRP53 protein binds to HSPB1 protein]] which results in increased expression of CDKN1A protein; [TRP53 protein results in decreased expression of SOD2 mRNA] which results in increased susceptibility to Doxorubicin; Celecoxib promotes the reaction [Doxorubicin results in increased expression of TRP53 protein]; Diclofenac promotes the reaction [Doxorubicin results in increased expression of TRP53 protein]; Doxorubicin affects the reaction [TRP53 protein binds to HSPB1 protein]; Doxorubicin promotes the reaction [[HSPB1 protein modified form results in increased activity of TRP53 protein] which results in increased expression of BAX protein]; Doxorubicin promotes the reaction [RELA protein binds to TRP53 protein]; Doxorubicin promotes the reaction [TDP 665759 results in increased expression of TRP53 protein]; Doxorubicin promotes the reaction [TRP53 protein binds to HSPB1 protein modified form]; Doxorubicin results in increased expression of and results in increased phosphorylation of TRP53 protein; Doxorubicin results in increased phosphorylation of and results in increased activity of TRP53 protein; HSF1 protein affects the reaction [Doxorubicin promotes the reaction [TRP53 protein binds to HSPB1 protein modified form]]; naringin inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]; pifithrin inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of TRP53 protein]; PSMB10 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; PSMB8 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; PSMB9 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Resveratrol inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]; SIRT1 protein affects the reaction [Doxorubicin results in increased expression of TRP53 protein]; SIRT1 protein affects the reaction [naringin inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]]; sirtinol inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]]; sulforaphane inhibits the reaction [TRP53 gene mutant form results in decreased susceptibility to Doxorubicin]; sulforaphane inhibits the reaction [TRP53 gene polymorphism results in decreased susceptibility to Doxorubicin]; TDP 665759 promotes the reaction [Doxorubicin results in increased expression of TRP53 protein]; TRP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TRP53 mutant form inhibits the reaction [Doxorubicin results in increased phosphorylation of STAT3 protein]; TRP53 protein mutant form affects the reaction [Doxorubicin results in increased activity of CASP3 protein]; TRP53 protein mutant form affects the reaction [Doxorubicin results in increased cleavage of PARP1 protein]; TRP53 protein mutant form promotes the reaction [Doxorubicin results in increased expression of XRCC5 protein]; TRP53 protein mutant form promotes the reaction [Doxorubicin results in increased expression of XRCC6 protein]; zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ANGPT1 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; 3-methyladenine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; 7-monohydroxyethylrutoside inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of TP53 mRNA; [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of TP53 protein; [Doxorubicin co-treated with Paclitaxel] results in increased expression of TP53 protein; [Doxorubicin co-treated with Resveratrol] results in increased expression of TP53 mRNA; [Doxorubicin co-treated with Resveratrol] results in increased expression of TP53 protein; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of TP53 protein; [Doxorubicin results in increased acetylation of TP53 protein mutant form] which results in increased expression of UBE2C protein; [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BAX mRNA; [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BBC3 mRNA; [NORAD co-treated with Doxorubicin] results in decreased expression of and results in decreased phosphorylation of TP53 protein; [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of TP53 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of ABL1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of ATM mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of ATR mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of ATRIP mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of ATRX mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of DDB2 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of ERCC2 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of EXO1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of FANCD2 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of FANCG mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of FEN1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of H2AX mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of LIG1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of MAPK12 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of MCPH1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of MDC1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of MPG mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of MSH3 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of NBN mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of NTHL1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of PCNA mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of PMS1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of PNKP mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of POLH mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of PPM1D mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of PPP1R15A mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of RAD1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of RAD17 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of RAD18 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of RAD21 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of RAD51 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of REV1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of RNF168 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of RNF8 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of TOPBP1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of XRCC1 mRNA; [TP53 protein affects the susceptibility to Doxorubicin] which affects the expression of XRCC2 mRNA; Acetylcysteine inhibits the reaction [ATM protein promotes the reaction [Doxorubicin results in increased activity of TP53 protein]]; Acetylcysteine inhibits the reaction [Doxorubicin promotes the reaction [ATM protein results in increased phosphorylation of TP53 protein]]; Acetylcysteine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; ANGPT1 protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; artenimol inhibits the reaction [TP53 protein mutant form results in increased export of Doxorubicin]; ATM protein promotes the reaction [Doxorubicin results in increased activity of TP53 protein]; Caffeine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; CDC25C protein inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Chloroquine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; cobaltous chloride inhibits the reaction [[Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BAX mRNA]; cobaltous chloride inhibits the reaction [[Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein] which results in increased expression of BBC3 mRNA]; cobaltous chloride inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]; cobaltous chloride inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]]; CSE1L protein promotes the reaction [Doxorubicin results in increased expression of TP53 protein]; diethoxyphosphoryloxymethyl butanoate promotes the reaction [Doxorubicin results in increased acetylation of TP53 protein]; Doxorubicin inhibits the reaction [TP53 protein binds to KDM8 protein]; Doxorubicin inhibits the reaction [TP53 protein binds to MDM2 protein]; Doxorubicin promotes the reaction [[CD40LG protein co-treated with IL4 protein] results in increased expression of TP53 protein]; Doxorubicin promotes the reaction [[TP53 protein binds to BBC3 promoter] which results in increased expression of BBC3 mRNA]; Doxorubicin promotes the reaction [ATM protein results in increased phosphorylation of TP53 protein]; Doxorubicin promotes the reaction [diethoxyphosphoryloxymethyl butanoate results in increased acetylation of TP53 protein]; Doxorubicin promotes the reaction [TP53 protein binds to BIRC5 promoter]; Doxorubicin promotes the reaction [TP53 protein binds to CARM1 protein]; Doxorubicin promotes the reaction [TP53 protein binds to CDKN1A promoter]; Doxorubicin promotes the reaction [TP53 protein binds to CREBBP protein]; Doxorubicin promotes the reaction [TP53 protein binds to ESR1 promoter]; Doxorubicin promotes the reaction [TP53 protein binds to JUN protein]; Doxorubicin promotes the reaction [TP53 protein binds to RRM2B promoter]; Doxorubicin promotes the reaction [TP53 protein binds to SP1 protein]; Doxorubicin results in increased expression of and affects the phosphorylation of and results in increased localization of TP53 protein; Doxorubicin results in increased expression of and results in increased phosphorylation of and results in increased acetylation of TP53 protein; Doxorubicin results in increased expression of and results in increased phosphorylation of TP53 protein; Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein; epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of TP53 protein]; Fluorouracil promotes the reaction [[Doxorubicin co-treated with Paclitaxel] results in increased expression of TP53 protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of TP53 mRNA]; Glutathione inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]; IFNA1 protein promotes the reaction [Doxorubicin results in increased expression of TP53 protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; MDM2 protein inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]]; MDM2 protein promotes the reaction [cobaltous chloride inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]]]; NFKB1 protein affects the reaction [Doxorubicin results in increased expression of TP53 protein]; nutlin 3 promotes the reaction [Doxorubicin results in increased expression of TP53 protein]; Oxygen deficiency inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; PI103 inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; pluronic block copolymer p85 promotes the reaction [Doxorubicin results in increased expression of TP53 mRNA]; SETD7 protein promotes the reaction [Doxorubicin results in increased stability of TP53 protein]; TNF protein inhibits the reaction [TP53 gene mutant form results in decreased susceptibility to Doxorubicin]; TP53 affects the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein]; TP53 affects the reaction [Doxorubicin results in increased activity of and results in increased expression of MDM2 protein]; TP53 affects the reaction [nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of CDKN1A protein]]; TP53 affects the reaction [nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of MDM2 protein]]; TP53 gene mutant form inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; TP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of ALOX12B mRNA]; TP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of ALOX5 mRNA]; TP53 gene mutant form inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TP53 protein affects the reaction [APP protein affects the susceptibility to Doxorubicin]; TP53 protein affects the reaction [CHEK1 protein affects the susceptibility to Doxorubicin]; TP53 protein affects the reaction [Doxorubicin affects the reaction [RELA protein results in increased expression of CDKN1A mRNA]]; TP53 protein affects the reaction [Doxorubicin results in decreased expression of BIRC5 protein]; TP53 protein affects the reaction [Doxorubicin results in decreased expression of EXO1 mRNA]; TP53 protein affects the reaction [Doxorubicin results in decreased expression of FANCD2 mRNA]; TP53 protein affects the reaction [Doxorubicin results in decreased expression of RAD1 mRNA]; TP53 protein affects the reaction [Doxorubicin results in decreased expression of RAD51 mRNA]; TP53 protein affects the reaction [Doxorubicin results in decreased expression of TERT mRNA]; TP53 protein affects the reaction [Doxorubicin results in decreased expression of TOPBP1 mRNA]; TP53 protein affects the reaction [Doxorubicin results in decreased expression of XRCC1 mRNA]; TP53 protein affects the reaction [Doxorubicin results in decreased expression of XRCC2 mRNA]; TP53 protein affects the reaction [Doxorubicin results in increased expression of ATRX mRNA]; TP53 protein affects the reaction [Doxorubicin results in increased expression of BAX protein]; TP53 protein affects the reaction [Doxorubicin results in increased expression of BBC3 protein]; TP53 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TP53 protein affects the reaction [Doxorubicin results in increased expression of ESR1 mRNA]; TP53 protein affects the reaction [Doxorubicin results in increased expression of ESR1 protein]; TP53 protein affects the reaction [Doxorubicin results in increased expression of GPX1 mRNA]; TP53 protein affects the reaction [Doxorubicin results in increased expression of NFKB1 protein]; TP53 protein affects the reaction [Doxorubicin results in increased expression of SOD2 mRNA]; TP53 protein affects the reaction [FHL2 protein affects the reaction [Doxorubicin results in increased expression of CDKN1A protein]]; TP53 protein affects the reaction [IFNA1 protein results in increased susceptibility to Doxorubicin]; TP53 protein inhibits the reaction [Doxorubicin results in decreased activity of CDK2 protein]; TP53 protein inhibits the reaction [Doxorubicin results in decreased expression of UBE2C protein]; TP53 protein inhibits the reaction [Sildenafil Citrate results in increased susceptibility to Doxorubicin]; TP53 protein mutant form affects the reaction [Doxorubicin results in decreased expression of BAX mRNA]; TP53 protein mutant form affects the reaction [Doxorubicin results in decreased expression of SFN mRNA]; TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of BAX protein]; TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of BBC3 protein]; TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of BCL2L1 protein]; TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]; TP53 protein mutant form affects the reaction [Doxorubicin results in increased expression of SFN protein]; TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]; TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]; TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]; TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]]; TP53 protein promotes the reaction [[Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased expression of BBC3 protein]; TP53 protein promotes the reaction [[Doxorubicin co-treated with PI103] results in increased expression of BBC3 protein]; TP53 protein promotes the reaction [Doxorubicin results in increased expression of ALOX12B mRNA]; TP53 protein promotes the reaction [Doxorubicin results in increased expression of ALOX5 mRNA]; TP53 protein promotes the reaction [Doxorubicin results in increased expression of FAS mRNA]; TP53 protein promotes the reaction [Doxorubicin results in increased expression of TNFSF10 mRNA]; TP53 protein promotes the reaction [Doxorubicin results in increased expression of TNFSF10 protein]; TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased activity of BAX protein]]; TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]; TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]; TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]; TP53 protein results in increased susceptibility to [Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]; TP53 protein results in increased susceptibility to [Doxorubicin co-treated with PI103]; Wortmannin inhibits the reaction [Doxorubicin promotes the reaction [ATM protein results in increased phosphorylation of TP53 protein]]; zinc chloride inhibits the reaction [cobaltous chloride inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]]